Stay updated with breaking news from Endoscopic Response. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Announced by AbbVie on October 15, 2023, positive results revealed 59% of patients treated with risankizumab and 40% of patients treated with ustekinumab achieved clinical remission, respectively.
More than half of patients in the mirikizumab arm achieved clinical remission at week 52.
This article will review risankizumab, a monoclonal antibody targeting interleukin 23 (IL-23) for the treatment of moderate to severe Crohn’s disease.
In this week’s edition: House passes Secure and Fair Enforcement (SAFE) Banking Act to protect proceeds from state-legal cannabis businesses from operation of money laundering laws, but has an unclear path in the Senate Senate Majority Leader Schumer and Sens. Booker and Wyden expected to introduce comprehensive cannabis reform legislation over objections from some Democratic colleagues Adult-use cannabis now legal in 17 US states, including, most recently, in New York, New Mexico and Virginia Florida Supreme Court strikes down ballot initiative that would have allowed Floridians to vote to...